China
Africa
Explore chapters and articles related to this topic
Welcome to the Intelligent Health Revolution
Published in Tom Lawry, Hacking Healthcare, 2022
Should this “look-back” conclude that you have a medical condition, you're told to stop smoking, start eating healthy, curb your alcohol intake, get on a new drug regimen, have a corrective medical procedure, or a host of other things that are reacting to a medical issue you now have.
Fenugreek (Methika)
Published in Dilip Ghosh, Prasad Thakurdesai, Fenugreek, 2022
Tanuja Manoj Nesari, Bhargav Bhide, Shivani Ghildiyal
An open-label, one-arm, non-randomized, post-marketing surveillance study in 50 premenopausal women (18–45 years, BMI < 42) diagnosed with PCOS using a novel Trigonella foenum-graecum seed extract (fenugreek seed extract, Furocyst, 2 capsules of 500 mg/day) enriched in approximately 40% furostanolicsaponins, over a period of 90 consecutive days was done. Approximately 46% of study population showed reduction in cyst size, while 36% of subjects showed complete dissolution of cyst. Further 71% of subjects reported the return of a regular menstrual cycle on completion of the treatment and 12% of subjects subsequently became pregnant. Overall, 94% of patients benefitted from the regimen. Significant increases in luteinizing hormone (LH) and follicular stimulating hormone (FSH) levels were observed compared to the baseline values. Extensive blood chemistry, haematological and biochemical assays demonstrated the broad-spectrum safety. Furocyst caused significant decrease in both ovarian volume and the number of ovarian cysts. Serum ALT, BUN, and CK were assessed to demonstrate the broad-spectrum safety of Furocyst. No significant adverse effects were observed. In summary, Furocyst was efficacious in ameliorating the symptoms of PCOS.30
The People and Their Drugs
Published in Mickey C. Smith, E.M. (Mick) Kolassa, Walter Steven Pray, Government, Big Pharma, and the People, 2020
Mickey C. Smith, E.M. (Mick) Kolassa, Walter Steven Pray
Whether a patient does or does not comply with their prescribed regimen and how they comply is determined in part by how the regimen interferes with her lifestyle and mobility needs. In part, it also depends upon how she comprehends or miscomprehends the uses and effects of therapy.
A concerning trend in geriatric pharmacy that merits evidence-based intervention
Published in Baylor University Medical Center Proceedings, 2022
Hunter Merritt Hughes, Hamasah Nizami, Juan Sebastian Polanco, Jessica Poulson, Alice Cai, Rea Mittal, Lilly Su, Pranjal Jain, Rohit Jain
Of note, both Wang et al and the American Academy of Family Physicians suggested the use of an interdisciplinary approach.26 Through this approach, the various aspects of patient well-being that are not often assessed by physicians, such as functional, cognitive, and nutritional states in addition to the presence of caregivers and social support, could be further explored and assessed. Consequently, patients can have a medication regimen tailored to their needs and environment. When this plan was enacted in patients 65 years and older in the Veteran Affairs system, there was a 35% decrease in risk of serious adverse drug effects compared to those who did not engage with interdisciplinary teams on an outpatient basis. Palliative care teams were not included in the study but could contribute to an interdisciplinary approach, especially during conversations about goals of care.26
Chapter 6: Tuberculosis preventive treatment in adults
Published in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022
Gonzalo G. Alvarez, Christopher Pease, Dick Menzies
TPT can be associated with a wide variety of adverse events (common adverse effects for each regimen are noted in Table 1). In general, mild to moderate adverse events (i.e., those not interfering with, or only modestly interfering with, instrumental activities of daily living, also known as Grade-1 and Grade-2 adverse events) should result in greater monitoring but do not necessarily require stopping therapy. However, severe adverse events that interfere with normal daily activity, including the ability to go to work (Grade 3) or any life-threatening or disabling adverse event (Grade 4) should lead to a pause in treatment until recovery or permanent discontinuation. A change to an alternative regimen should be considered once the patient has recovered. Detailed approaches to the management of specific adverse events have been published elsewhere.2,21
Spinal cord injury/dysfunction and medication management: a qualitative study exploring the experiences of community-dwelling adults in Ontario, Canada
Published in Disability and Rehabilitation, 2022
Lauren Cadel, Sander L. Hitzig, Tanya L. Packer, Tejal Patel, Aisha K. Lofters, Alison Thompson, Sara J. T. Guilcher
To our knowledge, this was the first qualitative study to explore the attitudes, beliefs and experiences of community-dwelling adults with SCI/D pertaining to medications and medication management. Importantly, medications were seen as disruptive because of the loss of control experienced with a complex medication regimen. Participants experienced a shift in their identity, as their previous reality that was free of medications was altered, forcing them to adapt. Participants feared changing their medication regimen due to concerns about re-experiencing debilitating secondary complications and concerns about potential side effects. Participants also incorporated a number of self-management strategies into their daily routines to help them manage their medications. Based on these results, two key implications were identified: (1) medication management is not a linear process; and (2) medication-taking experiences need to be understood more broadly by applying a self-management lens.